Preemptive clinical pharmacogenetics implementation: Current programs in five us medical centers

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 89-106

  Dunnenberger, Henry M ^a   Crews, Kristine R ^a   Hoffman, James M ^a   Caudle, Kelly E ^a   Broeckel, Ulrich ^b   Howard, Scott C ^a   Hunkler, Robert J ^c   Klein, Teri E ^d   Evans, William E ^a   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c IQVIA   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Clinical decision support; Individualized medicine; Personalized medicine; Pharmacogenomics; Precision medicine; Prediction in pharmacology

Indexed keywords

CLINICAL DECISION MAKING; DECISION SUPPORT SYSTEM; EDUCATION; ELECTRONIC MEDICAL RECORD; GENETIC VARIABILITY; GENOTYPE; HOSPITAL; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; UNITED STATES; UNIVERSITY HOSPITAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC SCREENING; GENETICS; HOSPITAL PHARMACY; MEDICAL EDUCATION; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PATIENT SAFETY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; RISK FACTOR;

ACADEMIC MEDICAL CENTERS; DECISION SUPPORT TECHNIQUES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EDUCATION, MEDICAL; GENETIC TESTING; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, ORGANIZATIONAL; PATIENT SAFETY; PATIENT SELECTION; PHARMACOGENETICS; PHARMACY SERVICE, HOSPITAL; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84920866837     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124835     Document Type: Review

References (74)

1. Meyer UA. 2004. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5:669-76
2. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. 2010. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet. Med. 12:686-93
3. Green ED, Guyer MS. 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470:204-13
4. Manolio TA, Green ED. 2011. Genomics reaches the clinic: from basic discoveries to clinical impact. Cell 147:14-16
5. Voora D, Ginsburg GS. 2011. A hub for bench-to-bedside pharmacogenomic-based research. Pharmacogenomics 12:1095-98
6. Wang L, McLeod HL, Weinshilboum RM. 2011. Genomics and drug response. N. Engl. J. Med. 364:1144-53
7. Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, et al. 2013. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin. Pharmacol. Ther. 95:141-46
8. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, et al. 2013. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94:640-45
9. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. 2013. Clinical Pharmacogenetics ImplementationConsortium guidelines for thiopurinemethyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93:324-25
10. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, et al. 2013. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94:317-23
11. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, et al. 2013. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94:324-28
12. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, et al. 2013. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93:402-8
13. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, et al. 2013. Clinical Pharmacogenetics ImplementationConsortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93:153-58
14. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, et al. 2012. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92:112-17
15. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. 2012. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91:734-38
16. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, et al. 2012. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of Cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91:321-26
17. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90:625-29
18. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90:328-32
19. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. 2011. Clinical Pharmacogenetics ImplementationConsortium guidelines for thiopurinemethyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89:387-91
20. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, et al. 2014. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95:376-82
21. Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin. Pharmacol. Ther. 96:169-74
22. Wu AC, Fuhlbrigge AL. 2008. Economic evaluation of pharmacogenetic tests. Clin. Pharmacol. Ther. 84:272-74
23. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360:753-64
24. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, et al. 2008. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84:326-31
25. Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, et al. 2009. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet. Genomics 19:103-12
26. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, et al. 2010. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87:572-78
27. Altman RB. 2013. Personal genomic measurements: the opportunity for information integration. Clin. Pharmacol. Ther. 93:21-23
28. Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR, et al. 2013. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 2:207-10
29. Altman RB, Whirl-Carrillo M, Klein TE. 2013. Challenges in the pharmacogenomic annotation of whole genomes. Clin. Pharmacol. Ther. 94:211-13
30. Hamburg MA, Collins FS. 2010. The path to personalized medicine. N. Engl. J. Med. 363:301-4
31. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, et al. 2012. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin. Pharmacol. Ther. 92:235-42
32. IMS Health. 2013. National prescription audit. HSRN data brief, Collegeville, PA
33. ODonnell PH, Bush A, Spitz J, Danahey K, Saner D, et al. 2012. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92:446-49
34. Pereira NL, Weinshilboum RM. 2011. The impact of pharmacogenomics on the management of cardiac disease. Clin. Pharmacol. Ther. 90:493-95
35. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. 2012. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92:437-39
36. Farrugia G, Weinshilboum RM. 2013. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin. Pharmacol. Ther. 94:204-6
37. Johnson JA. 2013. Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics 14:835-43
38. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. 2013. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 14:723-26
39. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, et al. 2012. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92:87-95
40. Relling MV, Altman RB, Goetz MP, Evans WE. 2010. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11:507-9
41. Scott SA. 2011. Personalizing medicine with clinical pharmacogenetics. Genet. Med. 13:987-95
42. Gottesman O, Scott SA, Ellis SB, Overby CL, Ludtke A, et al. 2013. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics- pharmacogenomics. Clin. Pharmacol. Ther. 94:214-17
43. Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, et al. 2014. Preemptive genotyping for personalizedmedicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin. Proc. 89:25-33
44. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, et al. 2008. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83:781-87
45. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, et al. 2011. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89:662-73
46. Pham HH, Schrag D, OMalley AS, Wu B, Bach PB. 2007. Care patterns in Medicare and their implications for pay for performance. N. Engl. J. Med. 356:1130-39
47. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, et al. 2012. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91:450-58
48. Relling MV, Klein TE. 2011. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89:464-67
49. McCullough KB, Formea CM, Berg KD, Burzynski JA, Cunningham JL, et al. 2011. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ. 75:51
50. Shields AE, Lerman C. 2008. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther. 83:635-39
51. Cohen J, Wilson A, Manzolillo K. 2013. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 13:378-88
52. Thorn CF, Klein TE, Altman RB. 2013. PharmGKB: the Pharmacogenetics and Pharmacogenomics Knowledge Base. Methods Mol. Biol. 1015:311-20
53. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, et al. 2014. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15:209-17
54. Eval. Genomic Appl. Pract. Prev. Work. Group. 2009. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11:15-20
55. Valdes R Jr, Payne D, Linder MW. 2010. Laboratory medicine practice guidelines: Laboratory analysis and application of pharmacogenetics to clinical practice. Rep., Natl. Acad. Clin. Biochem.
56. Eval. Genomic Appl. Pract. Prev. Work. Group. 2011. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet. Med. 13:67-76
57. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, et al. 2010. Diagnosis and management of autoimmune hepatitis. Hepatology 51:2193-213
58. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. 2011. British Association ofDermatologists guidelines for the safe and effective prescribing of azathioprine 2011. Br. J. Dermatol. 165:711-34
59. Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, et al. 2013. The NIH genetic testing registry: A new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 41:D925-35
60. Relling MV, Pui CH, Cheng C, Evans WE. 2006. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107:843-44
61. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, et al. 2011. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68:143-50
62. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, et al. 2009. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85:164-72
63. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. 2012. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92:467-75
64. Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, et al. 2014. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am. J. Med. Genet. Part C Semin. Med. Genet. 1:45-55
65. Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, et al. 2012. Concordance of DMET Plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92:360-65
66. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, et al. 2012. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92:563-66
67. Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, et al. 2013. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. e1:e93-99
68. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, et al. 2013. Clinically actionable genotypes among 10, 000 patients with preemptive pharmacogenomic testing. Clin. Pharmacol. Ther. 95:423-31
69. Oetjens MT, Denny JC, Ritchie MD, Gillani NB, Richardson DM, et al. 2013. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics 14:735-44
70. Overby CL, Kohane I, Kannry JL, Williams MS, Starren J, et al. 2013. Opportunities for genomic clinical decision support interventions. Genet. Med. 15:817-23
71. Goldspiel BR, Flegel WA, Dipatrizio G, Sissung T, Adams SD, et al. 2013. Integrating pharmacogenetic information and clinical decision support into the electronic health record. J. Am. Med. Inform. Assoc. 3:522-28
72. Welch B, Kawamoto K. 2013. The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J. Personalized Med. 3:306-25
73. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, et al. 2011. The emerging role of electronicmedical records in pharmacogenomics. Clin. Pharmacol. Ther. 89:379-86
74. Jaspers MWM, Smeulers M, Vermeulen H, Peute LW. 2011. Effects of clinical decision-support systems on practitioner performance and patient outcomes: A synthesis of high-quality systematic review findings. J. Am. Med. Inform. Assoc. 18:327-34